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Hemophagocytic lymphohistiocytosis (HLH) is a potentially fatal hyperinflammatory 
condition. Variants in different genes have been associated with the familial forms of 
the syndrome (FHL), usually presenting within the first 2 years of life. Due to increasing 
awareness of the signs and symptoms of HLH and a better understanding of the genetic 
basis of the disease, FHL has been increasingly diagnosed in patients presenting beyond 
infancy. Here, we report on two brothers with atypical, late-onset HLH in which whole 
exome sequencing revealed a homozygous pathogenic UNC13D variant. In the first 
brother, the clinical phenotype was dominated by a massive lung involvement. In the 
second brother a progressive neurological deterioration was observed. In both cases, 
the clinical manifestations at symptom onset were misleading, making the diagnosis 
difficult to achieve. This report expands the spectrum of clinical presentations of FLH3. 
Moreover, it highlights the importance to warn clinicians to keep a high level of suspicion 
in patients presenting with fever, cytopenia, splenomegaly of unknown origin, and unre-
sponsiveness to conventional treatment even beyond early childhood. Moreover, this 
report emphasizes that insidious neurologic symptoms may represent the initial or sole 
presenting sign of FHL, even in the absence of peripheral signs of activation.
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INtRoDUCtIoN
Hemophagocytic lymphohistiocytosis (HLH) is a potentially fatal hyperinflammatory condition 
characterized by prolonged and unexplained fever, unresponsiveness to conventional treatment, 
hepatosplenomegaly, cytopenia, hypertriglyceridemia, and hypofibrinogenemia (1, 2). Variants in 
four different genes have been associated with the familial forms of the syndrome (FHL). FHL-2 is 
due to variations in the PRF1 gene, encoding perforin 1, implicated in target cell lysis (3). UNC13D 
taBLe 1 | Comparison of clinical and laboratory markers in the two twins 
carrying the same UNC13D mutation.
patient 1 patient 2
UNC13D mutation Homozygous 
1847A>G
Homozygous 1847A>G
Age at onset 6.2 years 3 years
Symptoms at the onset Fever and severe 
dyspnea
Pervasive developmental 
disorder
Fever Yes No
Splenomegaly Yes Yes
CNS involvement No Yes
Lung involvement Massive bilateral 
consolidations
Signs of pulmonary 
hypertension
WBC (cells/mm3) 800 7,750
Neutrophil count (cells/mm3) 430 5,450
Lymphocyte count (cells/mm3) 320 1,880
Platelet count (cells/mm3) 27,000 241,000
Hemoglobin levels (g/dL) 7.8 14.9
Fibrinogen (mg/dL) 89 n.a.
Triglycerides (mg/dL) 1,556 110
Ferritin (ng/mL) 2,550 84
Albumin (gr/dL) 2.4 5
IgG/IgA/IgM (mg/dL) 315/46/58 487/45/120
IgE (IU/mL) 249 n.a.
CD3+ % (cells/mm3) 57% (182) 77.5%
CD4+ % (cells/mm3) 34% (109) 33%
CD8+ % (cells/mm3) 13% (42) 33.2%
CD19+ % (cells/mm3) 8% (26) 21%
CD16+ CD56+ % (cells/mm3) 22% (70) 1.5%
CD4+ CD45RA+ % (cells/mm3) n.a. 6.6%
CD4+ CD45RO+ % (cells/mm3) n.a. 26.4%
CD8+ CD45RA+ n.a. 14.9%
CD8+ CD45RO+ n.a. 18.3%
CD3+ HLADR+ 27% n.a.
Granule release assay n.a. Absent degranulation
Perforin expression n.a. Normal
Bone marrow aspirate Hypocellularity Lymphohistiocytic infiltration
CNS, central nervous system; WBC, white blood cells; n.a., not available.
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encoding MUNC13-4, STX11 encoding SYNTAXIN11, and 
STXBP2 encoding MUNC18-2 are implicated in the trafficking 
and exocytosis of lytic granules, and mediate the release at the 
cell surface of perforin1 and other effector molecules implicated 
in cytotoxicity (4–7). The impairment of the cytotoxic activity 
may lead to uncontrolled activation of cytotoxic T  cells and 
macrophages, which finally result in a hyperinflammation, T-cell, 
and macrophage infiltration of various organs including bone 
marrow, liver, and the central nervous system (8).
FHL usually presents within the first 2  years of life (9). 
However, the increasing awareness of the signs and symptoms 
of HLH and the better comprehension of the genetic basis of 
the disease allow the identification of FHL in patients present-
ing beyond infancy and sometimes before the development of 
the HLH (10). Atypical presentations have been reported in 
adolescents and even in adults, characterized by milder and often 
recurrent HLH episodes and prolonged survival in the absence 
of hematopoietic stem cell transplantation (HSCT), unusual in 
patients with the typical disease. Here, we report on two brothers 
with atypical, late-onset HLH in which whole exome sequencing 
(WES) revealed a homozygous pathogenic UNC13D variant. In 
both cases, the clinical manifestations at symptom onset were 
misleading, making the diagnosis difficult to achieve.
Case RepoRt
Written informed consent was obtained from the parents for 
the publication of both the cases. The patients were dizygotic 
twins born preterm (33 weeks) following conception by in vitro 
fertilization, yielding a triplet pregnancy complicated by 
in utero death of the third fetus. Parents were not consanguine-
ous and familial history was unremarkable, apart from a history 
of recurrent abortions in the mother. At the age of 6.2  years, 
after an uneventful childhood, the first brother developed fever 
resistant to antibiotics and severe, rapidly progressive dyspnea, 
requiring the admission to a pediatric intensive care unit for 
mechanical ventilation. The rapid progression of such a severe 
lung involvement raised the suspicion of a primary immunode-
ficiency (11). Clinical examination revealed splenomegaly and 
macular truncal rash. Laboratory examinations revealed triline-
age cytopenia, hypertriglyceridemia, hypofibrinogenemia, and 
hyperferritinemia (Table 1). The analysis of the bone marrow 
aspirate revealed hypocellularity, but lymphocytes and his-
tiocytes infiltration and hemophagocytosis were not observed. 
Lung Rx and CT scan revealed massive bilateral pulmonary 
consolidations with alveolar involvement, only sparing the api-
cal lobes (Figures 1A–C). Klebsiella pneumoniae and Candida 
albicans were isolated from the bronchial aspirate while the pleu-
ral fluid culture was negative. Nasal, pharyngeal and rectal swab, 
urine culture, mannan, galactomannan and PCR for HSV1/2, 
Parvovirus B19, HHV8, HHV6, CMV, EBV, and other respira-
tory viruses in the blood and bronchial aspirate were negative. 
Cytological examination of the pleural fluid showed an increase 
of the protein levels and of the leukocytes, in particular lympho-
cytes. Basal immunological examination revealed hypogam-
maglobulinemia (IgG 315 mg/dL, IgA 46 mg/dL, IgM 58 mg/
dL) with normal production of specific antibodies and a slight 
increase of IgE levels (249 IU/mL). A marked lymphopenia was 
observed, despite normal T, B, and NK cells percentages, apart 
from an increase of the CD3+ HLADR+ cells (Table 1). WES 
was performed due to suspicion of a CID with secondary HLH. 
Treatment with intravenous immunoglobulins, antibiotics, 
and antifungals was started. Venous extracorporeal membrane 
oxygenation (ECMO) was initiated due to the development of 
bilateral massive pneumothorax, but unfortunately the patient 
died of cardiopulmonary collapse.
The second brother developed a pervasive developmental 
disorder at the age of 3 years. By age 5, his neurological condition 
deteriorated with the development of asthenia, ataxia, and nys-
tagmus, facilitating a neurological evaluation. Brain MRI revealed 
areas of demyelination enhanced by contrast agent, involving 
pons, cerebellar peduncles, cerebellum, and white matter of 
the left temporal lobe (Figures 1D,E). CSF evaluation revealed 
pleocytosis and oligoclonal bands. Based on the radiological 
findings and favorable response to steroid treatment, a diagnosis 
of Chronic Lymphocytic Inflammation with Pontine Perivascular 
Enhancement Responsive to Steroids was suspected and the patient 
was started on Azathioprine. However, clinical and radiological 
findings deteriorated despite the immunosuppressive treatment 
FIgURe 1 | Radiological findings in the dizygotic twins homozygous for 1847A>G (p.Glu616Gly) in UNC13D. (a) Thoracic Rx of the patient 1; broad area of opacity 
involving the right mediobasal lobe and the left basal lobe, with bilateral hilar and perihilar infiltration. (B,C) Pulmonary CT scan of the patient 1; massive bilateral 
pulmonary consolidations with alveolar involvement, only sparing the apical lobes. (D,e) Brain MRI scan of the patient 2; T2w image with hyperintense signal in  
the left periventricular region, in pons, right cerebellar peduncles, and right cerebellar hemisphere. (F) Hematoxylin-eosin staining of the brain biopsy showing 
lymphohistiocytic perivascular and intraparenchymal inflammatory infiltrate (upper panel); immunohistochemical staining for the histiocytic marker CD68 (lower 
panel).
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and a brain biopsy was performed showing a lymphohistiocytic 
perivascular and intraparenchymal inflammatory infiltrate 
(Figure  1F). A CNS-HLH was suspected. Peripheral markers 
of activation were evaluated and found to be normal (Table 1). 
Splenomegaly and bone marrow lymphohistiocytic infiltration 
were detected. Immunological studies revealed normal IgG, IgA, 
and IgM levels and slightly increased CD3+ cells, mainly showing 
a memory phenotype, absent degranulation of the NK cells after 
the stimulus with K562 cells, normal perforin expression, suggest-
ing a diagnosis of HLH (Table 1).
In the first brother, WES revealed a homozygous pathogenic 
UNC13D variant, 1847A>G (p.Glu616Gly). This variant has 
been previously reported in affected individuals, and function-
ally demonstrated to result in deranged splicing of the gene 
(12, 13). It is absent from population databases. The second 
twin was genotyped for the variant by Sanger sequencing, 
revealing homozygosity for the same UNC13D variant. The 
parents were both heterozygous. A diagnosis of isolated CNS-
HLH was made, and the patient was started on the HLH-2004 
protocol. The patient unfortunately died of transplant-related 
complications.
DIsCUssIoN
Hemophagocytic lymphohistiocytosis represents the clinical 
and immunological manifestation of several diseases including 
FHL, characterized by a well-known pathogenic mechanism 
and a large number of disorders in which pathogenesis is still 
poorly understood. Indeed, HLH has been found in association 
with inborn errors of the metabolism (14–16), autoimmune 
disease (17), congenital immunodeficiencies, such as chronic 
granulomatous disease (18), DiGeorge syndrome (19), severe 
combined immunodeficiency (20), and X-linked agammaglobu-
linemia (21, 22), and other disorders (23–25). These last cases, 
described as “secondary” HLH, usually present in older children. 
More recently, the increasing awareness of the presenting signs 
of the disease and the development of new tools for the diagnosis 
of these conditions have made possible the identification also 
in patients presenting later in life with atypical symptoms (26). 
Considering the similarities between atypical FHL and secondary 
HLH, it can be difficult in some cases to achieve a rapid diagnosis. 
Moreover, in many cases of atypical FHL, the peripheral signs 
of HLH may be completely absent, making the diagnosis even 
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more difficult to achieve. In a recent paper, Gray et al reported 
on a case of late-onset FHL3 in which the clinical presentation 
was characterized by growth arrest, inflammatory arachnoiditis, 
and dysgammaglobulinemia, without any signs of HLH (10). 
Similarly, the hypomorphic A91V variation has been recently 
described in association with atypical late-onset HLH in a patient 
with neuromyelitis optica (27).
In this report, we describe two male dizygotic twins with 
atypical FHL3 (12, 13, 28). In both patients, the onset was delayed 
compared to the median age of 4.1 months reported in a wide 
cohort of FHL3 patients (13). Missense variants in UNC13D are 
associated with a later onset as compared with loss of function 
variants and median age at the diagnosis was 117.5 months in 
four patients with homozygous c.1847A>G (13). The two broth-
ers presented with very different clinical manifestations. In the 
first brother the clinical picture was dominated by a massive lung 
involvement and laboratory features suggested a secondary HLH 
in the context of a CID (24). WES failed to detect mutations other 
than UNC13D. However, even though primary immunodeficien-
cies have been traditionally considered as monogenic disorders, 
in the recent years high throughput sequencing techniques have 
highlighted that atypical phenotypes may be explained by the 
coexistence of multiple mutations (29–33). Since WES may 
not be able to detect large deletion/insertion and deep intronic 
mutations, we cannot exclude that a second mutation may 
have had a role in shaping such a complex clinical phenotype. 
On the other hand, even though immunological alterations are 
not usually found in patients with typical FHL, recent evidence 
suggests that different immunological alterations including 
antibody deficiency, low B-cell numbers, reduced percentage 
of marginal-zone like and class-switched memory B  cells, and 
susceptibility to bacterial sinopulmonary infections may be 
detected in patients with different forms of FHL (34). In some 
cases, hypogammaglobulinemia and defects of specific anti-
bodies developed after recurrent mild episodes of HLH (34). 
Interestingly, the immunological alterations are not usually found 
in patients with typical FHL, suggesting that in atypical forms a 
silent chronic T cell activation may impair the B cell development 
leading to the development of hypogammaglobulinemia (34). 
For this reason, the association of a clinical picture of common 
variable immunodeficiency/CID, with splenomegaly, cytopenia, 
and episodes of unexplained fever should address the diagnosis 
also toward atypical FHL (34).
Lung involvement is not well characterized in HLH, especially 
in pediatric patients and guidelines on the treatment of these 
conditions are also lacking (35). In a cohort of adult patients, 
lung involvement, due to lymphocytic infiltration or infection, 
was reported in about 54% of cases and associated with a worse 
prognosis (36). However, adult HLH may have a different patho-
genesis compared to children affected with FHL. In the patient 
described, Klebsiella pneumoniae and Candida albicans may have 
played a role in triggering the lung involvement and, moreover, the 
hypogammaglobulinemia along with the marked lymphopenia 
may have had a role in the rapid deterioration of the clinical condi-
tions. However, it should be noted that five out of eight HLH diag-
nostic criteria were present at the diagnosis (fever, splenomegalia, 
trilineage cytopenia, hyperferritinemia, hypofibrinogenemia/
hypertriglyceridemia), suggesting that HLH also had a role in 
shaping the clinical picture. Moreover, the patient did not show 
any sign of improvement despite 3 months of intravenous treat-
ment with immunoglobulins, different antifungals, and antibiot-
ics, suggesting an inflammatory more than infectious condition. 
Even though lung biopsy was not performed in our patients, all 
cultures, including pleural fluid were negative, with pleural fluid 
showing increased levels of proteins and lymphocytes, suggest-
ing lung infiltration by activated lymphocytes and histiocytes. 
In our patient, ECMO was initiated due to the development of 
bilateral massive pneumothorax. However, in a recent study on 
a small cohort of patients, survival of pediatric HLH patients on 
ECMO was worse than patients without HLH on ECMO (37). 
It should be noted that the severity of the clinical manifestations 
and the high mortality related to the lung involvement may them-
selves lead to a reduced estimation of the incidence of the lung 
involvement in FHL, since the patient may die without receiving 
a genetic diagnosis.
The second brother presented at the age of 3 years with signs 
of a pervasive developmental disorder. His neurological condi-
tions deteriorated progressively over a very long period. While 
lung infiltration is an unusual presentation of FHL (12, 13), 
neurologic signs are present in about 2/3 of the patients with 
FLH at the onset and may also develop later in the course of the 
disease (38, 39). Common neurological manifestations include 
irritability, seizures, bulging fontanel in infants, neck stiffness, 
hypotonia, and hypertonia (9, 40, 41). Other less common signs 
include nonspecific signs of increased intracranial pressure, 
cranial nerve palsy, ataxia, hemiplegia, quadriplegia, blindness, 
and coma (9, 40, 41). CSF examination usually shows elevated 
protein, increased number of mononuclear cells, and occasion-
ally hemophagocytosis (9, 40, 41). Typical radiologic findings 
include demyelination or impaired myelination, gray and white 
matter multifocal inflammation mimicking neuroinflammatory 
disorders including multiple sclerosis and acute disseminated 
encephalomyelitis (41, 42). FHL3 patients seem to be even more 
prone to develop CNS involvement. In a recent study, 60% of 
the patients with FHL3 showed a CNS involvement compared 
with the 32% in patients with FHL2 (13). Moreover, the variant 
identified in these twins has been frequently associated with CNS 
involvement (13). Of note, in our patient, more typical clinical 
neurological manifestations associated with HLH, including 
demyelination, ataxia, and cerebral palsy (43), were preceded by 
a pervasive developmental disorder, suggesting a very slow and 
insidious process which delayed the diagnosis. Moreover, the 
patient never showed any sign of systemic HLH. Previous evi-
dence suggest that primary HLH may also represent the underly-
ing cause of unknown CNS inflammation even in the absence 
of overt clinical signs of HLH, suggesting that FHL should be 
included in the differential diagnosis of unclassified progressive 
neuroinflammatory disease (44–50). T and NK cell degranulation 
assays and the evaluation of the expression of intracellular per-
forin can be used for the prompt identification of such patients, 
allowing a targeted treatment (51). Corticosteroids, etoposide, 
cyclosporine A, commonly used for the treatment of systemic 
HLH, along with intrathecal methotrexate and corticosteroids 
represent the standard, first-line therapeutic approach also for 
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the treatment of CNS-HLH (1, 9, 38). Antithymocyte globulin 
has also been used, in association with steroids, cyclosporin A, 
and intrathecal methotrexate injection to achieve remission in 
HLH (52). However, the efficacy of this association on CNS is 
comparable to the HLH-94 protocol (38, 52). HSCT also repre-
sents an important tool for the treatment of CNS-HLH especially 
in patients with familial forms, or with severe, persistent or 
reactivated HLH (38). Recently, novel therapeutic approaches 
are emerging as effective in the treatment of the refractory and 
complicated HLH even though many of these are still considered 
as second line or salvage experimental treatments. Among these, 
alemtuzumab has shown promising results in the treatment of the 
refractory HLH even though its effectiveness in the treatment of 
refractory CNS-HLH has not been clarified yet (53). Based on 
encouraging preclinical data from animal model, a clinical trial 
(NCT01818492) is currently ongoing to evaluate the efficacy of 
anti-IFNγ monoclonal antibody NI-0501 in the treatment of 
refractory HLH. Finally, the JAK1/2 inhibitor ruxolitinib has 
been recently shown to be effective in reducing the CNS involve-
ment in a Rab27a−/− mouse model (54).
CoNCLUDINg ReMaRKs
In conclusion, this report expands the spectrum of clinical 
presentations of FLH3. It is important to warn clinicians to keep 
a high level of suspicion in patients presenting with fever, cyto-
penia, splenomegaly of unknown origin, and unresponsiveness 
to conventional treatment even beyond early childhood. 
Moreover, it must be emphasized that insidious neurologic 
symptoms may represent the initial or sole presenting sign of 
FHL, even in the absence of any overt clinical manifestations of 
HLH. Considering that in FHL3 diagnostic delay may be fatal 
or result in irreversible neurologic sequelae, clinicians should 
be aware that unclassified neuroinflammatory diseases could 
be the sole initial sign of FHL. In this context, next-generation 
sequencing techniques and flow cytometric assays may play 
an important role in addressing the diagnosis. The precocious 
diagnosis of these conditions is pivotal to establish the best 
therapeutic approach.
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